Evidence map›Paper›PMID 19549850›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2009

Essential role of the Ly49A stalk region for immunological synapse formation and signaling.

Daisuke Ito, Yoshie-Matsubayashi Iizuka, Madhu P Katepalli, Koho Iizuka

Abstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Daisuke ItoDivision of Hematology, Oncology, and Transplantation, Department of Medicine, Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA.
Yoshie-Matsubayashi Iizuka
Madhu P Katepalli
Koho Iizuka

Funding

MHC Class l-independent NK Cell RegulationR21AI064270 · NIAID · UNIVERSITY OF MINNESOTA TWIN CITIES · PI IIZUKA, KOHO · 2005 to 2006
$392k
EXTRAMURAL RESEARCH FACILITIES CONTRUCTION PROJECTSC06CA062526 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI KERSEY, JOHN H · 1993 to 1993
–
NCI NIH HHS C06 CA062526NCI NIH HHS CO6 CA062526-01NIAID NIH HHS R21 AI064270NIAID NIH HHS R21AI064270
6 · The paper itself

Abstract

NK cells use surface NK receptors to discriminate self from non-self. The NK receptor ligand-binding domain (NKD) has been considered the sole regulator of ligand binding. Using a prototypic murine NK receptor, Ly49A, we show that the membrane proximal nonligand binding ecto-domain (the stalk region) is critical to ligand binding and signaling. The stalk region is required for receptor binding to ligand on target cells (trans interaction), but is dispensable for receptor binding to ligand on the same cell (cis interaction). Also, signaling in a trans manner depends on the stalk region mediating the formation of the immunological synapse. Thus, our data modeling receptor function at the cellular level reveal an essential role for the stalk region as a specific mediator of receptor signal integration, by which NKD-ligand interactions at the interface initiate and deliver information to the spatially separated cytoplasmic domain.

Indexed as

Amino Acid SequenceAnimalsGene DeletionGenes, ReporterImmunological SynapsesLigandsMiceModels, ImmunologicalMolecular Sequence DataNK Cell Lectin-Like Receptor Subfamily AProtein BindingProtein FoldingProtein Structure, TertiaryRecombinant Fusion ProteinsSignal TransductionSolubilityKlra1 protein, mouseLigandsNK Cell Lectin-Like Receptor Subfamily ARecombinant Fusion Proteins

Identifiers

PMID19549850
PMCPMC2708761

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.